TY - CHAP M1 - Book, Section TI - Nonoperative Treatments For Lung Cancer Percutaneous Thoracic Tumor Ablation A1 - Wee, Jon O. A2 - Sugarbaker, David J. A2 - Bueno, Raphael A2 - Colson, Yolonda L. A2 - Jaklitsch, Michael T. A2 - Krasna, Mark J. A2 - Mentzer, Steven J. A2 - Williams, Marcia A2 - Adams, Ann Y1 - 2015 N1 - T2 - Adult Chest Surgery, 2e AB - Lung cancer remains the leading cause of cancer death for both men and women.1 Only one-third of patients diagnosed with lung cancer are stage appropriate for surgical therapy. In addition, the rising population of elders in the United States and other Western countries has caused an increase in the number of patients with comorbidities, making primary surgical and curative therapy more complicated. In fact, a review of the California cancer registry revealed that stage I cancer patients who received no treatment have a median survival of 9 months. Eighty-nine percent of patients who were recommended for treatment but refused died within 5 years, and 78% of these patients died from cancer-specific causes. For T1 lesions, the survival rate for treated cancers was 155 months versus 26 months for untreated cancers.2 For those patients treated with conventional external radiation alone, 5-year survival is 10% to 30%.3 Hence, appropriate treatment even for patients with major comorbidities should be available. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesssurgery.mhmedical.com/content.aspx?aid=1105842994 ER -